

Second Circuit Finds “Product Hopping” By a Pharmaceutical Company to Violate Antitrust Laws

May 29, 2015 | Client Update

In *New York v. Actavis PLC*, No. 14-4624 (2nd Cir. May 22, 2015), the United States Court of Appeals for the Second Circuit became the first appellate court to address a pharmaceutical industry practice known as “product hopping.”

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

Arthur J. Burke

+1 212 450 4352
+1 650 752 2005
arthur.burke@davispolk.com

Arthur F. Golden

+1 212 450 4388
arthur.golden@davispolk.com

Ronan P. Harty

+1 212 450 4870
ronan.harty@davispolk.com

This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.

Related materials

[Read the full update](#)